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Introduction: Corticosteroid injections and foot orthoses are common interventions for plantar heel pain.
Previous clinical trials have found that the effectiveness of these interventions differs over time, with
corticosteroid injections being more effective in the short-term (i.e. 0e4 weeks) and foot orthoses more
effective in the longer-term (i.e. 5e12 weeks). However, some of these trials have methodological
weaknesses that could have caused confounding and bias, which may have led to over- or under-
estimation of the effectiveness of these interventions. As a result, there is a need to compare the
effectiveness of corticosteroid injections and foot orthoses in a robust clinical trial with an appropriate
follow-up time.
Methods: This article describes the protocol for a pragmatic, parallel-group assessor-blinded randomised
trial (Steroid injection versus foot orthoses (SOOTHE) heel pain trial). One hundred participants with
plantar heel pain will be randomly allocated (i.e. two groups of approximately 50) to receive either an
ultrasound-guided corticosteroid injection or prefabricated foot orthoses. Outcome measures will be
obtained at baseline, 4, 8 and 12 weeks, with two primary endpoints at 4 and 12 weeks to reﬂect the
hypothesised temporal effects of each intervention. The primary outcome measure will be the foot pain
domain of the Foot Health Status Questionnaire.
Trial registration: Australian and New Zealand Clinical Trials Registry number ACTRN12615001266550.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Plantar heel pain (PHP) is one of the most common musculo-
skeletal conditions affecting the lower limb. The worldwide prev-
alence of PHP in the population is unknown, however it appears to
be most common in middle-aged and older people, and in runners.
In a sample of the general adult population in Australia who re-
ported foot pain, 21% reported pain in the heel [1]. An investigation
of an older sample in the United States found a PHP prevalence of
6.9% [2], and in the United Kingdom, PHP accounts for approxi-
mately 7.5% of all musculoskeletal foot and ankle general practiceA. Whittaker), s.munteanu@
.au (H.B. Menz), aelzarka@
.B. Landorf).
Inc. This is an open access article uconsultations [3]. In a North American study that collected injury
data on runners who presented to a sports medicine clinic over a 2-
year period, the incidence of PHPwas 7.9% and it was the thirdmost
common running-related injury reported [4]. PHP causes signiﬁ-
cant mobility limitation [5,6], and individuals with PHP exhibit
poorer health-related quality of life [6].
Corticosteroid injections and foot orthoses are common in-
terventions used to treat PHP [7]. Clinical guidelines published by
the American Physical Therapy Association [8] recommend foot
orthoses as an initial treatment option, while the American College
of Foot and Ankle Surgeons [9] recommend both corticosteroid
injections and foot orthoses as initial treatment options. Previous
research indicates that corticosteroid injections are more effective
at reducing pain than placebo injections in the short-term (i.e. 4e6
weeks), but the effect is unclear in the longer-term (i.e. 8e12
weeks) [7]. In contrast, trials comparing foot orthoses to sham foot
orthoses have reported inconsistent effects in the short-term (i.e.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in the longer-term (i.e. at 12 weeks) [12,13]. Based on this
research, corticosteroid injections may be more effective in the
short-term, while foot orthoses may be more effective in the
longer-term. At this stage, corticosteroid injections and foot or-
thoses have not been directly evaluated in robust randomised
trials, and consequently, nor has the temporal difference between
the two interventions.
Two randomised trials have compared the effectiveness of
corticosteroid injections and foot orthoses, however the ﬁndings
were inconsistent [14,15]. The trials had methodological short-
comings including high participant attrition [14], use of non-
standardised outcome measures, and one trial had a relatively
short follow-up period (i.e. 4 weeks) [15]. As a result, there is un-
certainty regarding which intervention is more appropriate for
health practitioners to recommend to individuals with PHP, or
whether one should be recommended for short-term beneﬁt, while
the other recommended for longer-term beneﬁt. Given corticoste-
roid injections and foot orthoses are both common interventions, it
is important that health practitioners have robust evidence from
which they can make decisions regarding treatment for PHP.
Therefore, a high-quality randomised trial is needed to clarify in-
consistencies in past research, and provide ﬁndings that can be
readily adopted by health practitioners.
The primary aim of this study is to compare the effectiveness of
corticosteroid injections to foot orthoses for PHP. Speciﬁcally, we
seek to determine whether corticosteroid injections are more
effective at reducing pain in the short-term (i.e. 0e4 weeks) and
foot orthoses are more effective at reducing pain in the longer-term
(i.e. 5e12 weeks). Our secondary aims are to investigate differences
in ‘ﬁrst-step’ pain, function, health-related quality of life, and fear-
avoidance beliefs over time.2. Methods
This trial has been registered on the Australian and New Zealand
Clinical Trial Registry (ACTRN12615001266550). All publications
related to this trial will be reported in accordance with the CON-
SORT Guidelines for reporting randomised trials [16].2.1. Design
This study will be a pragmatic, parallel-group assessor-blinded
randomised trial. Due to the nature of the interventions, therapists
and participants will not be blinded, however the assessor
measuring outcomes will be blind to group allocation (i.e. therewill
be assessor blinding). Fig. 1 displays the ﬂow of participants
through the trial. Participants will be allocated to one of two
groups:
Group 1 e corticosteroid injection: participants will receive a
single ultrasound-guided corticosteroid injection into the affected
heel(s) of 1 mL of betamethasone (Celestone®, Merck Sharp and
Dohme, Macquarie Park, Australia) mixed with 1 mL of bupivacaine
(Marcaine®, AstraZeneca, North Ryde, Australia), a long-acting local
anaesthetic.
Group 2 e foot orthoses: participants will receive a pair of For-
mthotics™ (Footscience International, Christchurch, New Zealand)
prefabricated foot orthoses.
Both groups will also be provided a stretching program, written
and verbal advice regarding PHP and wearing suitable footwear.
Accordingly, the only difference between the two groups is that
Group 1 will receive a corticosteroid injection and Group 2 will
receive foot orthoses.2.1.1. Initial appointment
Prior to the initial appointment, potential participants will be
screened via telephone to ensure they satisfy inclusion criteria (as
outlined in Section 2.5) that can be provided verbally. At the initial
appointment, potential participants will be further screened to
ensure they satisfy all remaining inclusion criteria requiring
assessment (as outlined in Section 2.5). All participants will be
provided with a participant information statement and will give
informed consent prior to being included into the trial. Following
this, participant characteristics such as sex, height, weight, dura-
tion of symptoms, foot posture (measured using the Foot Posture
Index e 6), medications and major medical conditions will be
recorded. Ultrasonography will be performed to assess plantar
fascia thickness and the presence of hypoechogenicity. To measure
plantar fascia thickness, two measurements will be recorded. A
longitudinal scan will measure (i) the maximum thickness in the
proximal third of the plantar fascia, and (ii) the thickness of the
plantar fascia as it crosses the anterior aspect of the inferior
calcaneal border. The measurements will be performed with a
variable frequency (5e10 MHz) linear array transducer (Acuson
Aspen; Siemens Medical Solutions, PA, USA). Measuring plantar
fascia thickness as it crosses the anterior aspect of the inferior
calcaneal border has been used previously [17,18] and has good
intra-rater reliability (intra-class correlation coefﬁcient ¼ 0.86
[95% CI, 0.77e0.92]) [19]. There is no accepted method of assessing
hypoechogenicity, however previous studies have assessed hypo-
echogenicity as being either present or absent, which has been
reported to have moderate intra-rater reliability (Cohen's Kappa
ranging between 0.59 and 0.69) [19]. For bilateral cases, the most
painful foot will be evaluated to satisfy the assumption of inde-
pendent data [20]; this method has been used in previous heel
pain research [21]. All remaining patient-reported outcome mea-
sures will be obtained at this appointment.
2.1.2. Intervention appointment
Following randomisation, participants will attend their second
appointment where they will receive their allocated intervention.
Participants randomised to the corticosteroid injection group will
be referred to a radiologist at a medical imaging centre, who will
perform a single ultrasound-guided corticosteroid injection into
the affected heel. Participants randomised to the foot orthosis
group will be referred to a podiatrist at the La Trobe University
Health Sciences Clinic to have the orthoses ﬁtted.
2.2. Randomisation, allocation concealment and blinding
Following the initial appointment for eligibility screening and
inclusion into the trial, participants will be randomised to one of
two groups. Randomisation and allocation to groups will be con-
ducted using an interactive voice response telephone service
provided by the National Health and Medical Research Council
(NHMRC) Clinical Trials Centre at the University of Sydney, New
South Wales, Australia. Adaptive stratiﬁcation (i.e. minimisation)
will be used to minimise baseline imbalance in the groups (factors
to be included are sex, BMI and duration of symptoms), and
permuted block randomisation with uneven random block sizes
will be undertaken. Participants will be advised of their allocation
by a secondary investigator who will not be involved with any
other part of the trial. Following allocation, participants will con-
tact one of two therapists (a radiologist for the corticosteroid in-
jection or a podiatrist for the foot orthoses), who will arrange an
appointment for the participant to receive the allocated
intervention.
Given the nature of the interventions, it is not possible to blind
the therapists and participants. However, the therapists will have
Fig. 1. Study ﬂow diagram.
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All outcome assessments will be conducted by the primary inves-
tigator (GAW) who will be blind to group allocation. Prior to each
outcome assessment, and to minimise the chance of the outcome
assessor becoming unblinded, participants will be advised not to
discuss their allocated intervention during the follow-up
appointments.2.3. Interventions
2.3.1. Ultrasound-guided corticosteroid injection
Participants randomised to Group 1 will receive a single
ultrasound-guided corticosteroid injection from a qualiﬁed radiol-
ogist (AE). The injection technique will be based on the method
used by Yucel et al. [15]. Participants will be placed in a prone
position with their feet hanging from the end of the examination
table. Following this, an ultrasound probewill be positioned to scan
the fascia longitudinally and then a 25-gauge needle will be
inserted through the medial heel approximately 1 cm above the
weightbearing line of the skin (Fig. 2). A solution of 1 mL of a
combination of betamethasone acetate and betamethasone sodium
phosphate (Celestone® Chondrose) mixed with 1mL of bupivacaine(Marcaine® 0.5%) will be injected. Inﬁltrationwill be directed to the
region surrounding the area of maximum plantar fascia thickening
(i.e. there will be no inﬁltration into the plantar fascia itself) and
aseptic technique will be maintained throughout the procedure.
Prior to leaving the radiological clinic, participants will be advised
to avoid running and high impact activities for two weeks. Partic-
ipants with bilateral PHP will have both feet treated, and will
receive the second injection the following day to ensure that there
are no signiﬁcant adverse events associated with the initial
injection.2.3.2. Foot orthoses
Participants randomised to Group 2 will receive a pair (i.e. one
for each foot) of Formthotics™ prefabricated foot orthoses (Fig. 3).
The style of Formthotics™ provided will be full length, and man-
ufactured from a dual-density polyethylene closed cell foam that
has a ﬁrm-density bottom layer (Shore-A durometer 50), and a soft-
density top layer (Shore-A durometer 25). Participants will receive
the foot orthoses in accordance with the manufacturer's in-
structions. The foot orthoses are initially heated and then placed in
the participants' footwear. Once positioned correctly, the partici-
pants will then be asked to stand on the orthoses in a ‘corrected’
Fig. 2. Technique for administering the ultrasound-guided corticosteroid injection.
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thoses to mould to the foot. This type of foot orthosis is an arch-
contouring device that has been used in previous PHP research
[12,22]. The foot orthoses will be ﬁtted based on the participant's
foot and shoe size. Any necessary adjustments to ensure correct
ﬁtting will be made during the treatment appointment.
2.3.3. Interventions provided to both groups
2.3.3.1. Stretching program. In addition to the experimental in-
terventions provided (corticosteroid injection to Group 1 and foot
orthoses to Group 2), participants in both groups will receive
plantar fascia and calf stretches, which are regarded as ‘usual care’
and a common co-intervention in PHP research [17,23e27]. The
stretching program will be based on the program evaluated by
DiGiovanni et al. [28]. For the plantar fascia stretches, prior toFig. 3. Formthotics™ dual-densitstanding in the morning, the participant will cross their foot over
their contralateral knee, dorsiﬂex their toes and ankle, and then
hold the stretch (Fig. 4a). The calf stretches will be performed
immediately after rising in the morning, and involve placing one
foot directly behind the contralateral limb while leaning into a wall
(Fig. 4b and c). Both the plantar fascia and calf stretches will be
performed daily for a duration of 10 s and repeated 10 times.2.3.3.2. Plantar heel pain and footwear education. Participants in
both groupswill receive education on PHP andwearing appropriate
footwear (e.g. appropriately ﬁtting footwear, suitable ﬁxation,
cushioning). Education will be provided verbally, and with a
handout explaining PHP (Appendix A.1).2.4. Outcome measures
Outcome measures will be obtained at baseline, 4, 8 and 12
weeks. The trial will have two primary endpoints at 4 and 12weeks.
Two primary endpoints (4 and 12 weeks) have been selected to
ascertain if either of the interventions is more effective in the short-
term or longer-term. To reduce the burden on participants in the
trial, outcome measures will be either posted or emailed for the 8-
week follow-up, and therefore, there will be no requirement for
participants to attend in person. As a result, no ultrasound outcome
measures will be reported at 8 weeks. Participants with bilateral
PHP will be instructed to complete patient-reported outcome
measures with respect to the most painful foot.2.4.1. Primary outcome measure
The primary outcome measure will be the foot pain domain of
the Foot Health Status Questionnaire (FHSQ) [29]. The FHSQ is a 13-
item questionnaire used to evaluate foot-speciﬁc health-related
quality of life. It has four domains or sub-scales (foot pain, foot
function, footwear, and general foot health). The questionnaire uses
a Likert scale format for participants to indicate their foot health
from one (e.g. ‘none’) to ﬁve (e.g. ‘severe’). The foot pain domain
contains four questions that measure the type, frequency and in-
tensity of pain over the previous week. The FHSQ has been shown
to be valid (content, criterion and construct), have high test-retest
reliability (intra-class correlation coefﬁcients ranging from 0.74 to
0.92), and a high degree of internal consistency (Cronbach's a
ranging from 0.85 to 0.88) [29]. In addition, the minimal important
difference has been calculated for the foot pain domain in partici-
pants with PHP [30]. The FHSQ has been used in previous trials
investigating interventions for PHP [12,17,21], and a recent review
recommended its use in PHP research [8].y prefabricated foot orthosis.
Fig. 4. Plantar fascia and calf stretches: (a) plantar fascia stretch; (b) calf stretch with knee extended; (c) calf stretch with knee ﬂexed.
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Secondary outcomemeasures will be used to assess other issues
related to pain, function (i.e. foot-related disability), and under-
stand factors that may predict clinical outcome. These include:
(i) Severity of ‘ﬁrst step’ pain and average pain over the last
seven days, measured on a 100 mm visual analogue scale
(VAS) at baseline, 4, 8 and 12 weeks;
(ii) Foot function measured on the foot function domain of the
FHSQ [29] at baseline, 4, 8 and 12 weeks;
(iii) Plantar fascia thickness measured sonographically [17,18] at
baseline, 4 and 12 weeks;
(iv) Plantar fascia hypoechogenicity measured sonographically
[19] at baseline, 4 and 12 weeks;
(v) Generic health-related quality of life will be measured with
the EQ-5D questionnaire [31] at baseline, 4, 8 and 12 weeks;
(vi) Generic health-related quality of life will also be measured
with the Short Form 36® version 2 (SF-36) [32] at baseline, 4,
8 and 12 weeks;
(vii) Self-reported physical activity measured using the 7-day
Physical Activity Recall Questionnaire [33] at baseline, 4, 8
and 12 weeks;
(viii) Fear-avoidance beliefs measured using the Fear-avoidance
Components Scale (FACS) [34] measured at baseline, 4, 8
and 12 weeks;
(ix) Global perceived rating of change measured with a 15-point
Likert scale at 4, 8 and 12 weeks;
(x) Days of work lost over the previous week due to PHP
measured at baseline, 4, 8 and 12 weeks;
(xi) Sessions of sports or exercise lost over the previous week
measured at baseline, 4, 8 and 12 weeks;
(xii) Use of co-interventions for foot pain measured at 4, 8 and 12
weeks;
(xiii) The participant's preference for treatment (i.e. corticosteroid
injection, foot orthoses or no preference), which will be
asked at baseline [35].2.5. Participants
Participants will be adults aged 18 years or older, who are living
independently in the community. Table 1 outlines the inclusion and
exclusion criteria for the study. Participants will be recruited
through advertisements in local newspapers and magazines,
posters placed at universities, health clubs and senior citizen cen-
tres, web-based advertising on health noticeboards and forums,and social media (e.g. Facebook, Twitter).
2.6. Ethical approval
Ethical approval will be obtained prior to the trial commencing
from the La Trobe University Human Ethics Committee. The trial
will adhere to the National Health and Medical Research Council's
Statement on Ethical Conduct in Human Research [37], and all
participants will sign informed consent prior to inclusion in the
trial.
2.7. Adverse effects
Adverse effects at the time of the corticosteroid injectionwill be
managed and recorded in line with standard medical practice by
the radiologist administering the injection. Other adverse effects,
such as additional foot pain due to wearing foot orthoses or pain
related to the injection, will be recorded at each time-point (i.e. 4, 8
and 12 weeks). Participants will be asked to document the type of
adverse effect, and the frequency or severity of the effect. If par-
ticipants experience more signiﬁcant adverse effects (e.g. infection)
they will be advised to contact one investigator who is not involved
in recruitment, allocation or data collection (SEM or KBL). Any
adverse effects will be reported in the ﬁnal manuscript.
2.8. Evaluation of adherence
The evaluation of adherence will be assessed during the
outcome assessments at 4, 8 and 12 weeks. Adherence to the foot
orthoses will be documented, with participants being asked how
many days they have worn their foot orthoses over the last week,
and for howmany hours each day. Both groups will also be asked to
document how many days over the last week they have performed
the plantar fascia and calf stretches, and whether they have
changed their footwear since their last outcome assessment.
2.9. Sample size
The sample size for the trial has been determined using an a
priori power analysis based on the primary outcome measure, the
foot pain domain of the Foot Health Status Questionnaire (FHSQ)
[29] at week 12. The minimal important difference for this measure
in individuals with PHP has previously been determined as 12.5
points [30]. Using a standard deviation derived from previous PHP
research of 21 [17,38], a power level of 0.8, alpha level of 0.05, and a
Table 1
Inclusion and exclusion criteria.
Inclusion criteria
(i) Aged 18 years or older;
(ii) Have a clinical diagnosis of PHP in accordance with the clinical practice guidelines linked to the International Classiﬁcation of Function, Disability and Health from the
Orthopaedic Section of the American Physical Therapy Association [8], which includes:
a. Pain in the plantar medial heel region that is aggravated by weightbearing activities or worse in the morning and/or after a period of rest;
b. Pain upon palpation of the medial calcaneal tubercle;
(iii) A duration of PHP of at least 4 weeks;
(iv) Report their average pain over the last seven days as at least 30 mm on a 100 mm VAS [36];
(v) Be willing to regularly wear foot orthoses for the duration of the trial;
(vi) Be willing and have no contraindications to receive a corticosteroid injection in the plantar heel;
(vii) Be willing to attempt to not use any other forms of treatment during the trial (with the exception of paracetamol up to 4 g/day).
Exclusion criteria
(i) Unable to understand the English language;
(ii) Unable to walk household distances unaided;
(iii) Have received treatment for PHP in the last 4 weeks;
(iv) Have received a corticosteroid injection in the previous six months;
(v) Have regularly worn foot orthoses within the previous six months;
(vi) Have a history of surgery to the heel;
(vii) Have a systemic medical condition such as a connective tissue disease, degenerative neurological disorder or inﬂammatory disorder;
(viii) Currently pregnant or likely to become pregnant during the trial;
(ix) Unwilling to regularly wear footwear that can accommodate foot orthoses.
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trials for PHP, this has typically been <5%) [12,17,39,40], a sample
size of 100 participants (i.e. approximately 50 per group) will be
required for adequate statistical power. We have conservatively
ignored the extra precision provided by covariate analysis when
estimating the sample size. This sample size will also be sufﬁcient
to: (i) explain the variance in the foot pain domain of the FHSQ at
baseline, and (ii) predict improvement in the foot pain domain of
the FHSQ between baseline and 12 weeks.2.10. Data analysis
Statistical analysis will be undertaken using SPSS version 22.0
(IBM Corp, NY, USA). All analyses will follow the intention-to-
treat principle [16] for all randomised participants, and missing
data will be accounted for using multiple imputation, with age,
BMI, baseline scores and group allocation entered as predictors
[41]. For bilateral cases, the most painful foot will be evaluated to
satisfy the assumption of independent data [20] e this method
has been used in previous PHP research [21]. Standard tests of the
distribution of continuous data will be undertaken, and trans-
formations applied to skewed data if appropriate. If data are not
normally distributed and cannot be transformed, they will be
handled non-parametrically.
The differences between the two groups for primary and sec-
ondary outcome measures will be analysed at 4, 8 and 12 weeks,
with 4 and 12 weeks being the primary endpoints. The primary
endpoints have been chosen to allow investigation of the primary
aim of the trial; that is, that there may be temporal differences in
the effectiveness of the two interventions. Continuous data will be
analysed using a regression approach to analysis of covariance
(ANCOVA) with the baseline score for each continuous outcome
measure used as a covariate [42,43]. For example, for comparisons
of pain at each of the time-points, adjustments will be made for
pain at baseline. Dichotomous outcomes will be compared using
risk ratios and number needed to treat where appropriate. All
comparisons for outcome measures will be reported as point esti-
mates with 95% conﬁdence intervals and p-values.3. Discussion
The primary aim of this randomised trial is to compare the
effectiveness of corticosteroid injections to foot orthoses for in-
dividuals with PHP. This trial has been pragmatically designed to
inform health practitioners about the effectiveness of the in-
terventions in the short-term (i.e. 0e4 weeks) and longer-term (i.e.
5e12 weeks).
It is important to explore the effectiveness between corticoste-
roid injections and foot orthoses as they are both common in-
terventions used to treat individuals with PHP, and previous trials
comparing these interventions have reported inconsistent ﬁndings
with respect to pain and function [14,15]. The ﬁrst trial conducted
by Lynch et al. [14], was a three group trial comparing: (i) a corti-
costeroid injection (dexamethasone acetate) plus an oral non-
steroidal anti-inﬂammatory drug, (ii) customised foot orthoses
plus taping, and (iii) a viscoelastic heel cup. The authors completed
their ﬁnal follow-up at 12 weeks and concluded that customised
foot orthoses were more effective than either the corticosteroid
injection or the viscoelastic heel cup. However, this trial exhibited
substantial participant attrition, with only 57% of participants
providing outcome data at 12 weeks, and the investigators did not
employ an intention-to-treat analysis. In addition, it is unclear what
speciﬁc effect the corticosteroid injection had on pain reduction as
the corticosteroid injection was provided in conjunction with an
oral non-steroidal anti-inﬂammatory drug that was not provided to
participants in the other groups.
The second trial by Yucel et al. [15] compared a corticosteroid
injection (reported as a combined betamethasone, trade-name
Kenakort-A Retard® manufactured by Bristol-Myers Squibb) to a
silicone prefabricated foot orthosis. The trial found a greater
reduction in VAS pain, plantar fascia thickness, and Foot and Ankle
Outcome Scores (FAOS) for pain, sport and recreation, and activities
of daily living in the group receiving the corticosteroid injection.
However, this trial's primary endpoint was 4 weeks (i.e. short-term
only).
Four additional randomised trials [17,18,44,45] have evaluated
corticosteroid injections against either a placebo or another type of
injection. Similar to the Yucel et al. trial [15], three of these trials
found a signiﬁcant reduction in pain in the short-term (i.e. 4 weeks)
G.A. Whittaker et al. / Contemporary Clinical Trials Communications 5 (2017) 1e11 7for individuals receiving a corticosteroid injection, but this reduc-
tion was not maintained after 4 weeks [17,44,45]. In contrast, the
fourth trial by Ball et al. [18] found a sustained effect of a cortico-
steroid injection (methylprednisolone acetate) compared to pla-
cebo (saline) at both 6 and 12 weeks. The inconsistencies observed
in these trials may have been due to the type of corticosteroid used,
with acetates (e.g. methylprednisolone acetate) tending to have a
longer duration of action than phosphates (e.g. betamethasone
sodium phosphate) [46].
In addition to evaluating the effectiveness of these interventions
reducing pain, previous trials have also evaluated the effectiveness
of foot orthoses and corticosteroid injections at improving function.
Three randomised trials have found improvements in function
[11e13], and the most recent systematic review concluded cus-
tomised foot orthoses are more effective than sham foot orthoses at
improving function up to 12 months [7]. However, there has been
limited research evaluating the effectiveness of corticosteroid in-
jections to improve function. McMillan et al. [17] included function
as a secondary outcome, ﬁnding no difference between a cortico-
steroid injection and a placebo injection. Two previous trials that
compared corticosteroid injections to foot orthoses [14,15] included
function as an outcomemeasure, but the ﬁndingswere inconsistent
between the trials. Lynch et al. [14] assessed the effect of cortico-
steroid injections and foot orthoses on leisure, work, and exercise,
however no informationwas provided on how these were assessed
and whether it was valid. They found no signiﬁcant difference in
these functional outcomes between the corticosteroid injection and
foot orthosis groups at 12 weeks. In contrast, Yucel et al. [15] used
the validated Foot and Ankle Outcome Score (FAOS) to assess
function and health-related quality of life. After 4 weeks, FAOS
activities of daily living and sport and recreation subscales improved
more in the corticosteroid injection group than the foot orthosis
group. Although, Yucel at al [15] used a validated outcome measure
to assess function, the endpoint was 4 weeks, compared to the
endpoint for Lynch et al. [14] trial being 12 weeks, which makes
comparison between the two difﬁcult. Given individuals with PHP
report signiﬁcant foot-related disability [5,6,47], it is important to
better understand the inﬂuence of these interventions on function.
Regarding the experimental interventions that will be evaluated
in this trial, an ultrasound-guided corticosteroid injection using
betamethasone sodium phosphate combined with betamethasone
acetate has been selected. There is no consensus for the most
suitable corticosteroid to use for soft tissue injections, and differ-
ences in corticosteroid preference have been reported between
practitioners [48]. Rheumatology guidelines published in Australia
recommend two corticosteroids - betamethasone sodium phos-
phate combined with betamethasone acetate, or triamcinolone
acetonide [49]. Betamethasone sodium phosphate combined with
betamethasone acetate has been selected for use in this trial due to
the combination of a long-acting acetate, which will increase po-
tency, and a short-acting sodium phosphate which will increase
solubility. This combination will balance the potency required for
an anti-inﬂammatory action [46], against greater solubility which
will decrease the likelihood of adverse effects such as plantar fascia
rupture or fat pad atrophy [50]. An ultrasound-guided injection has
been chosen as ultrasound-guided injections have been found to be
more effective than palpation guided injections [51].
The type of foot orthoses selected for this trial are prefabricated
arch-contouring devices rather than customised foot orthoses.
Prefabricated foot orthoses have been demonstrated to have similar
effectiveness to customised foot orthoses for PHP [52,53]. No
research has investigated what features of foot orthoses are more
effective for PHP, however a few studies have investigated kinetic
(i.e. plantar pressure) changes using different foot orthoses. Arch-
contouring devices have been shown to reduce peak plantarpressure and maximum force at the plantar heel [22,54], and there
is some evidence to show that they reduce plantar fascia strain
[55,56]. Based on this previous research, the Formthotics™ used in
this trial, which are arch contouring devices, will serve to reduce
both plantar fascia strain and vertical ground reaction forces at the
plantar heel. In addition, the prefabricated foot orthosis selected
has been used in previous PHP research [12,22,54].
The additional standard care interventions (i.e. stretching pro-
gram) provided to both groups have been selected to reﬂect clinical
practice, and allow the results to be generalisable. Plantar fascia and
calf stretches are commonly provided by a wide variety of health
practitioners, there is no associated cost, and they have been
demonstrated to be effective for PHP [28,40,57]. A number of
randomised trials investigating PHP have provided stretches to
participants in both groups [17,23e27], and to reﬂect common
clinical practice, these standard stretches will be provided to both
groups in our trial.
4. Conclusions
This article outlines the protocol for an assessor-blinded, par-
allel-group randomised trial to compare the effectiveness of a
single corticosteroid injection to foot orthoses for PHP. The trial has
been designed to speciﬁcally investigate whether there are tem-
poral differences between the interventions (e.g. a corticosteroid
injection is more effective in the short-term and a foot orthosis is
more effective in the longer-term). In addition, the trial will also
assess variables that may predict clinical outcome. Finally, the
pragmatic design of the trial, including a representative
community-based recruitment process and commonly imple-
mented interventions, will reﬂect everyday practice and ensure
that the ﬁndings are generalisable.
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